Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company has obtained 226 product registration certificates and holds 57 patents, recognized as a high-tech enterprise [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin stands at 57.98% [2] Market Position - As of August 5, the company's stock closed at 118.7 yuan, with a rolling PE ratio of 217.57 times, significantly higher than the industry average of 54.24 times and the median of 37.92 times [1][3] - The total market capitalization is 7.535 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in Haobio, with a total of 1.1392 million shares valued at 155 million yuan [1]
浩欧博收盘下跌1.32%,滚动市盈率217.57倍,总市值75.35亿元